Grant D. MacLean

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

K. Swenerton, J Jeffrey, Gavin Stuart et al. · Journal of Clinical Oncology · 1992 · 214 citations

Antibodies Against Mucin-Associated Sialyl-Tn Epitopes Correlate with Survival of Metastatic Adenocarcinoma Patients Undergoing Active Specific Immunotherapy with Synthetic STn Vaccine

Grant D. MacLean, Mark A. Reddish, R. Rao Koganty et al. · Journal of Immunotherapy · 1996 · 183 citations

Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant

Grant D. MacLean, Mark Reddish, R. Rao Koganty et al. · Cancer Immunology Immunotherapy · 1993 · 183 citations · Full text

Breast Oncology, Detox Adjuvant, Synthetic Sialyl-tn Glycoconjugate +15

Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer

Martin Palmer, Joanne L. Parker, Shanu Modi et al. · Clinical Lung Cancer · 2001 · 159 citations

Muc1 Peptide, Tumor Immunology, Medicine +12

Enhancing the Effect of THERATOPE STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide

Grant D. MacLean, D.W. Miles, R.D. Rubens et al. · Journal of Immunotherapy · 1996 · 157 citations